You want safer, more effective and affordable symptom management. Not a cannabis booster.
You want someone who can help you learn and guide you to your optimal cannabis regimen.
And you want to partner with experts who understand how to work with people who often have complicated health and medication profiles.
Our clinician-led team is here to answer any questions you have and help you use cannabis most wisely.
Meet PEP, our always-on, clinician-created and AI-powered personalized cannabis education platform. Have questions? PEP is always here.
Currently in BETA, PEP is a ChatGPT-powered cannabis education and guidance service. It uses rules and prompts devised by eo’s clinical team in an effort to provide cannabis information that’s as personally relevant and clinically responsible as possible. The more PEP is used, the more it is “trained” and the more accurate it becomes.
PEP’s primary source of information is its ever-growing library of respected cannabis research (we value recent research from established academic and government sources above all). Secondarily, PEP sources information from trusted academic, government and cannabis industry research that is publicly available on the Internet.
While all the content PEP displays is informed by our clinician-created rules and prompts, it will display 3rd-party research sources whenever appropriate.
We’ve designed PEP to minimize the risk of incorrect answers and/or “hallucinations” but it’s still learning and it may provide erroneous or sub-optimal answers from time-to-time.
‍
For this reason, we’ve designed PEP to never offer specific product, dose or time of use recommendations. (This is the domain of eo’s unique data model-driven care plan recommendation platform, whose outputs are always reviewed by a clinician). Â
Most of all, before beginning any cannabis use for medical or wellness reasons, you should always check with your primary care physician and/or an expert eo cannabis clinician.
Yes. PEP is fully HIPAA compliant. And you can read more about eo’s privacy policy here.
A pioneering palliative care clinician and researcher, Dr. Worster is currently Director, Supportive Oncology at Jefferson Health in Philadelphia. She is a graduate of Temple University School of Medicine and completed her fellowship in palliative care and pain management at MGH Brigham and Dana Farber Cancer Center in Boston.
A pioneering palliative care clinician and researcher, Dr. Worster is currently Director, Supportive Oncology at Jefferson Health in Philadelphia. She is a graduate of Temple University School of Medicine and completed her fellowship in palliative care and pain management at MGH Brigham and Dana Farber Cancer Center in Boston.
An internationally recognized cannabis clinician and educator, Dr. Caplan has overseen the care of over 18,000 cannabis patients and developed protocols that have benefited tens of thousands more. He is a graduate of Tufts University School of Medicine and completed his residency in family medicine at Boston Medical Center.
An internationally recognized cannabis clinician and educator, Dr. Caplan has overseen the care of over 18,000 cannabis patients and developed protocols that have benefited tens of thousands more. He is a graduate of Tufts University School of Medicine and completed his residency in family medicine at Boston Medical Center.
A leading clinical geriatric pharmacist and educator, Dr. Hajjar serves as Professor and Director of the Population Health Pharmacy Program at the Jefferson College of Pharmacy. She received her PharmD at Duquesne University and completed a fellowship in Geriatric Pharmacoepidemiology at the University of Minnesota.
A leading clinical geriatric pharmacist and educator, Dr. Hajjar serves as Professor and Director of the Population Health Pharmacy Program at the Jefferson College of Pharmacy. She received her PharmD at Duquesne University and completed a fellowship in Geriatric Pharmacoepidemiology at the University of Minnesota.
Rollouts in new markets, new partnerships, research initiatives and special offers are all coming soon.